- Home
- NIE vs ABUS Comparison
NIE vs ABUS Comparison
Compare NIE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- ABUS
- Stock Information
- Founded
- NIE 2007
- ABUS 2005
- Country
- NIE United States
- ABUS United States
- Employees
- NIE N/A
- ABUS N/A
- Industry
- NIE Investment Managers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- ABUS Health Care
- Exchange
- NIE Nasdaq
- ABUS Nasdaq
- Market Cap
- NIE 697.4M
- ABUS 672.1M
- IPO Year
- NIE N/A
- ABUS N/A
- Fundamental
- Price
- NIE $23.19
- ABUS $3.36
- Analyst Decision
- NIE
- ABUS Strong Buy
- Analyst Count
- NIE 0
- ABUS 4
- Target Price
- NIE N/A
- ABUS $5.50
- AVG Volume (30 Days)
- NIE 70.5K
- ABUS 843.8K
- Earning Date
- NIE 01-01-0001
- ABUS 05-14-2025
- Dividend Yield
- NIE 9.04%
- ABUS N/A
- EPS Growth
- NIE N/A
- ABUS N/A
- EPS
- NIE N/A
- ABUS N/A
- Revenue
- NIE N/A
- ABUS $6,403,000.00
- Revenue This Year
- NIE N/A
- ABUS $14.57
- Revenue Next Year
- NIE N/A
- ABUS $15.84
- P/E Ratio
- NIE N/A
- ABUS N/A
- Revenue Growth
- NIE N/A
- ABUS N/A
- 52 Week Low
- NIE $18.61
- ABUS $2.71
- 52 Week High
- NIE $22.47
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- NIE 63.11
- ABUS 53.55
- Support Level
- NIE $23.00
- ABUS $3.04
- Resistance Level
- NIE $23.37
- ABUS $3.54
- Average True Range (ATR)
- NIE 0.30
- ABUS 0.14
- MACD
- NIE -0.01
- ABUS 0.02
- Stochastic Oscillator
- NIE 73.03
- ABUS 70.00
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.